LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
07 oct. 2021 11h31 HE
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma...
LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
16 août 2021 07h05 HE
|
Lava Therapeutics N.V.
Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metastatic castrate resistant...
LAVA Therapeutics提供企业更新信息并报告第二季度业绩
16 août 2021 07h05 HE
|
Lava Therapeutics N.V.
评估LAVA-051针对血液恶性肿瘤效果的1/2a期试验的患者招募工作正在继续 评估LAVA-1207针对转移性去势抵抗性前列腺癌效果的1/2a期试验的CTA已被接受，IND得到许可；有望在今年晚些时候开始 与Janssen Biotech, Inc.的合作一直在顺利进行，并正在朝着预计的里程碑迈进 预计将为2023年下半年的业务提供1.51亿美元现金余额 荷兰乌得勒支和费城, Aug. ...
LAVA Therapeutics宣布任命Amy Garabedian为总法律顾问兼公司秘书
28 juil. 2021 08h28 HE
|
Lava Therapeutics N.V.
荷兰乌得勒支和费城, July 28, 2021 (GLOBE NEWSWIRE) -- 专注于开发双特异性γ-δ T细胞衔接抗体以改变癌症治疗的临床阶段生物技术公司LAVA Therapeutics N.V.（Nasdaq: LVTX）今天宣布，任命Amy Garabedian为总法律顾问兼公司秘书。Garabedian女士是位经验丰富的领导者，在生命科学行业拥有广泛的企业和事务专业知识。 ...
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary
27 juil. 2021 08h00 HE
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific...
LAVA Therapeutics宣布在LAVA-051治疗多种血液系统恶性肿瘤的1/2a期临床试验开始首位患者给药
13 juil. 2021 08h56 HE
|
Lava Therapeutics N.V.
荷兰乌得勒支和费城, July 13, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics NV（纳斯达克股票代码：LVTX）是一家专注于开发双特异性γ-δ T细胞衔接抗体（bsTCE）以改变癌症治疗方式的生物技术公司。该公司今天宣布，其针对复发性和/或难治性慢性淋巴细胞白血病（CLL）、多发性骨髓瘤（MM）和急性髓系白血病（AML）患者的LAVA-051...
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
13 juil. 2021 07h00 HE
|
Lava Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, July 13, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on developing bispecific gamma-delta T cell...
LAVA Therapeutics将参加2021年Jefferies医疗保健虚拟大会
25 mai 2021 07h51 HE
|
LAVA Therapeutics BV
荷兰乌得勒支和费城, May 25, 2021 (GLOBE NEWSWIRE) -- 专注于运用其双特异性γ-δ T细胞结合物专业知识来改变癌症疗法的生物技术公司LAVA Therapeutics N.V.（纳斯达克代码：LVTX）今天宣布，其首席执行官Stephen Hurly将出席美国东部时间2021年6月1日星期二上午11:30举行的2021年Jefferies医疗保健 虚拟大会。 ...
LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference
25 mai 2021 06h30 HE
|
LAVA Therapeutics BV
UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta...
LAVA Therapeutics提供企业更新信息并报告第一季度财务业绩
20 mai 2021 10h46 HE
|
LAVA Therapeutics BV
IPO将现金和现金等价物的资产负债表增加到1.6亿美元；预计将可为至少2023年下半年以前的运营提供资金 血液和实体肿瘤项目的临床开发计划在按计划进行 通过关键管理和董事会任命加强了领导能力 荷兰乌得勒支和美国费城, May 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics...